CTOs on the Move

Covidien

www.covidien.com

 
Covidien Ltd. (Covidien) is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Covidien is part of the local fabric of the communities in which we operate around the world. Our success is made possible through the dedication of our 43,000 employees, nearly two-thirds of whom work in 51 manufacturing facilities located in 18 countries. Every day, over 5,500 Covidien sales representatives meet the needs of our customers in 70 countries. In all, our Company derives 45% of its sales from outside the United States. Covidien, formerly Tyco Healthcare, is a medical ...
  • Number of Employees: 50K-100K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Pacific Biomarkers

Pacific Biomarkers is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

US Eye

Be a part of something bigger. Enhance your eye care practice’s capabilities by partnering with a team that understands your business. Contact us today.

Hospice Provider Group Inc

Hospice Provider Group Inc is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Direct Pharmacy Service

Direct Pharmacy Service is a Lanham, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.